PMID- 30988766
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 17
IP  - 5
DP  - 2019 May
TI  - DL-3-n-butylphthalide therapy for Parkinson's disease: A randomized controlled 
      trial.
PG  - 3800-3806
LID - 10.3892/etm.2019.7397 [doi]
AB  - Currently available treatments for Parkinson's disease (PD) do not delay or 
      prevent disease development and progression. DL-3-n-butylphthalide (NBP), 
      isolated from Apium graveolens seeds, alleviates oxidative damage and 
      mitochondrial dysfunction. It has been revealed to reduce the loss of dopamine 
      neurons in pre-clinical PD models, and has been approved for the treatment of 
      ischemic stroke patients. The purpose of the present study was to examine whether 
      NBP has the capacity provide a benefit for PD patients and to slow disease 
      progression. A randomized, controlled trial was performed between September 2014 
      and December 2016. Pairs of patients matched by age, gender and off-medication 
      Unified PD Rating Scale motor subscale (UPDRS-III) scores, were randomly assigned 
      to an NBP treatment group and a control group. All patients continued their 
      originally prescribed medication regimen and those in the NBP group were 
      administered NBP at 200 mg three times daily for 24 weeks. Primary outcome 
      measures were changes in UPDRS-III, including tremor score and non-tremor score, 
      the Pittsburgh sleep quality index (PSQI) and the PD 39-items questionnaire (PDQ) 
      scores. Assessments were completed by blinded evaluators at baseline and 12, 24 
      and 48 weeks after randomization. All patients were monitored for adverse events 
      (AEs). A total of 103 patients were enrolled in the present study. The NBP group 
      exhibited significantly greater improvements in the non-tremor, PSQI and PDQ-39 
      scores than the control group, which generally exhibited no improvement. 
      NBP-associated AEs were uncommon and primarily consisted of mild gastrointestinal 
      symptoms. In conclusion, over the 6-month treatment period, NBP was safe and 
      effective for improving the symptoms and impairing the progression of patients 
      with PD (Trial registry number, ChiCTR1800018892).
FAU - Zhou, Haiyan
AU  - Zhou H
AD  - Department of Gerontology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu, Anhui 233004, P.R. China.
FAU - Ye, Ming
AU  - Ye M
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Xu, Wenfang
AU  - Xu W
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Yu, Meiling
AU  - Yu M
AD  - Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Liu, Xiaolin
AU  - Liu X
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Chen, Yuhua
AU  - Chen Y
AD  - Department of Neurology, Anhui Provincial Hospital Affiliated to Anhui Medical 
      University, Hefei, Anhui 230001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190314
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6447885
OTO - NOTNLM
OT  - DL-3-n-butylphthalide
OT  - Parkinson's disease
OT  - Unified Parkinson's Disease Rating Scale motor subscale III
OT  - randomized controlled trial
EDAT- 2019/04/17 06:00
MHDA- 2019/04/17 06:01
PMCR- 2019/03/14
CRDT- 2019/04/17 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/12/21 00:00 [accepted]
PHST- 2019/04/17 06:00 [entrez]
PHST- 2019/04/17 06:00 [pubmed]
PHST- 2019/04/17 06:01 [medline]
PHST- 2019/03/14 00:00 [pmc-release]
AID - ETM-0-0-7397 [pii]
AID - 10.3892/etm.2019.7397 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 May;17(5):3800-3806. doi: 10.3892/etm.2019.7397. Epub 2019 Mar 
      14.